Savara reports Q1 EPS (15c), consensus (14c)

“With approximately $203M in cash and, upon MOLBREEVI approval, access to up to an additional $150Min non-dilutive capital through debt and royalty structures, we remain well capitalized to fund global commercial launch preparations,” said Matt Pauls, Chair and CEO, Savara (SVRA). “With a PDUFA action date of November 22nd, U.S. commercial planning momentum is building. Our newly deployed Rare Disease Specialists are actively driving disease awareness for autoimmune PAP and advancing launch readiness initiatives for MOLBREEVI-a potentially first and only treatment for autoimmune PAP.”